IRIS Accounts Production v24.2.0.383 09691337 Board of Directors 1.1.23 31.12.23 31.12.23 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh096913372022-12-31096913372023-12-31096913372023-01-012023-12-31096913372021-12-31096913372022-01-012022-12-31096913372022-12-3109691337ns15:EnglandWales2023-01-012023-12-3109691337ns14:PoundSterling2023-01-012023-12-3109691337ns10:Director12023-01-012023-12-3109691337ns10:PrivateLimitedCompanyLtd2023-01-012023-12-3109691337ns10:SmallEntities2023-01-012023-12-3109691337ns10:AuditExemptWithAccountantsReport2023-01-012023-12-3109691337ns10:SmallCompaniesRegimeForDirectorsReport2023-01-012023-12-3109691337ns10:SmallCompaniesRegimeForAccounts2023-01-012023-12-3109691337ns10:FullAccounts2023-01-012023-12-310969133712023-01-012023-12-3109691337ns10:Director22023-01-012023-12-3109691337ns10:Director32023-01-012023-12-3109691337ns10:Director42023-01-012023-12-3109691337ns10:RegisteredOffice2023-01-012023-12-3109691337ns5:CurrentFinancialInstruments2023-12-3109691337ns5:CurrentFinancialInstruments2022-12-3109691337ns5:ShareCapital2023-12-3109691337ns5:ShareCapital2022-12-3109691337ns5:RetainedEarningsAccumulatedLosses2023-12-3109691337ns5:RetainedEarningsAccumulatedLosses2022-12-3109691337ns5:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-3109691337ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2022-12-3109691337ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-01-012023-12-3109691337ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-12-3109691337ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2022-12-3109691337ns5:FurnitureFittings2022-12-3109691337ns5:FurnitureFittings2023-01-012023-12-3109691337ns5:FurnitureFittings2023-12-3109691337ns5:FurnitureFittings2022-12-3109691337ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-12-3109691337ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-12-3109691337ns5:RetainedEarningsAccumulatedLosses2022-12-3109691337ns5:RetainedEarningsAccumulatedLosses2023-01-012023-12-31
REGISTERED NUMBER: 09691337 (England and Wales)















CHARLWOOD PHARMA LIMITED

Unaudited Financial Statements

for the Year Ended 31 December 2023






CHARLWOOD PHARMA LIMITED (REGISTERED NUMBER: 09691337)

Contents of the Financial Statements
for the year ended 31 December 2023










Page

Company Information 1

Accountants' Report 2

Balance Sheet 3

Notes to the Financial Statements 5


CHARLWOOD PHARMA LIMITED

Company Information
for the year ended 31 December 2023







Directors: E M C Farrant
W Potter
A Farrant
L J Potter





Registered office: Trotwood
The Firs
Odiham
Hook
Hampshire
RG29 1PP





Registered number: 09691337 (England and Wales)





Accountants: Cooper Parry Advisory Limited
178 Buckingham Avenue
Slough
Berkshire
SL1 4RD

Accountants' Report to the Board of Directors
on the Unaudited Financial Statements of
Charlwood Pharma Limited


The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Directors' Report are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Charlwood Pharma Limited for the year ended 31 December 2023 which comprise the Income Statement, Balance Sheet and the related notes from the company's accounting records and from information and explanations you have given us.

This report is made solely to the Board of Directors of Charlwood Pharma Limited, as a body, in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Charlwood Pharma Limited and state those matters that we have agreed to state to the Board of Directors of Charlwood Pharma Limited, as a body, in this report. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that Charlwood Pharma Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Charlwood Pharma Limited. You consider that Charlwood Pharma Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Charlwood Pharma Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






Cooper Parry Advisory Limited
178 Buckingham Avenue
Slough
Berkshire
SL1 4RD


16 September 2024

CHARLWOOD PHARMA LIMITED (REGISTERED NUMBER: 09691337)

Balance Sheet
31 December 2023

2023 2022
Notes £ £
Fixed assets
Intangible assets 4 123,115 99,012
Tangible assets 5 5,501 -
128,616 99,012

Current assets
Debtors 6 317,621 378,070
Cash in hand 570,131 411,655
887,752 789,725
Creditors
Amounts falling due within one year 7 (391,562 ) (353,230 )
Net current assets 496,190 436,495
Total assets less current liabilities 624,806 535,507

Capital and reserves
Called up share capital 8 104 104
Retained earnings 9 624,702 535,403
Shareholders' funds 624,806 535,507

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

CHARLWOOD PHARMA LIMITED (REGISTERED NUMBER: 09691337)

Balance Sheet - continued
31 December 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 30 August 2024 and were signed on its behalf by:





W Potter - Director


CHARLWOOD PHARMA LIMITED (REGISTERED NUMBER: 09691337)

Notes to the Financial Statements
for the year ended 31 December 2023


1. Statutory information

Charlwood Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. Accounting policies

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The directors have considered the impact on the business of the economic uncertainty arising from Covid-19 pandemic alongside the measures that have been taken to mitigate that impact. Based on these assessments and the current resources available, the directors believe it is reasonable to adopt the going concern basis in preparing the financial statements.

Turnover
Turnover represents net invoiced sales of goods and services, excluding value added tax.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost
less any accumulated amortisation and any accumulated impairment losses.

Licence costs are being amortised evenly over their estimated useful life of three years.

Tangible fixed assets
Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Fixtures and fittings - 33% straight line

Financial instruments
Trade and other debtors and creditors are classified as basic financial instruments and measured at initial recognition at transaction price. Debtors and creditors are subsequently measured at amortised cost using the effective interest rate method. A provision is established when there is objective evidence that the company will not be able to collect all amounts due.

Cash and cash equivalents are classified as basic financial instruments and comprise cash in hand and at bank and bank overdrafts which are an integral part of the company's cash management.

Financial liabilities and equity instruments issued by the company are classified in accordance with the substance of the contractual arrangements entered into and the definitions of a financial liability and an equity instrument. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Financial assets and financial liabilities are recognised in the balance sheet when the company becomes a party to the contractual provisions of the instrument.


CHARLWOOD PHARMA LIMITED (REGISTERED NUMBER: 09691337)

Notes to the Financial Statements - continued
for the year ended 31 December 2023


2. Accounting policies - continued
Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Research and development
Expenditure on research and development is written off in the year in which it is incurred.


Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. Employees and directors

The average number of employees during the year was 4 (2022 - 4 ) .

4. Intangible fixed assets
Licence
costs
£
Cost
At 1 January 2023 143,318
Additions 56,456
At 31 December 2023 199,774
Amortisation
At 1 January 2023 44,306
Amortisation for year 32,353
At 31 December 2023 76,659
Net book value
At 31 December 2023 123,115
At 31 December 2022 99,012

CHARLWOOD PHARMA LIMITED (REGISTERED NUMBER: 09691337)

Notes to the Financial Statements - continued
for the year ended 31 December 2023


5. Tangible fixed assets
Fixtures
and
fittings
£
Cost
At 1 January 2023 6,080
Additions 6,137
At 31 December 2023 12,217
Depreciation
At 1 January 2023 6,080
Charge for year 636
At 31 December 2023 6,716
Net book value
At 31 December 2023 5,501
At 31 December 2022 -

6. Debtors: amounts falling due within one year
2023 2022
£ £
Trade debtors 314,621 377,392
Other debtors 3,000 678
317,621 378,070

7. Creditors: amounts falling due within one year
2023 2022
£ £
Trade creditors 241,813 142,682
Taxation and social security 109,906 79,374
Other creditors 39,843 131,174
391,562 353,230

CHARLWOOD PHARMA LIMITED (REGISTERED NUMBER: 09691337)

Notes to the Financial Statements - continued
for the year ended 31 December 2023


8. Called up share capital

Allotted, issued and fully paid:

Number: Class: Nominal 2023 2022
Value: £    £   
100 Ordinary £1 100 100
1 A ordinary £1 1 1
1 B ordinary £1 1 1
1 C ordinary £1 1 1
1 D ordinary £1 1 1
104 104

9. Reserves
Retained
earnings
£

At 1 January 2023 535,403
Profit for the year 169,299
Dividends (80,000 )
At 31 December 2023 624,702